Compare AIOT & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIOT | DNA |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 665.1M | 562.3M |
| IPO Year | N/A | N/A |
| Metric | AIOT | DNA |
|---|---|---|
| Price | $5.21 | $8.31 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 4 | 1 |
| Target Price | ★ $10.50 | $9.00 |
| AVG Volume (30 Days) | ★ 1.2M | 992.7K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $425,867,000.00 | $180,606,000.00 |
| Revenue This Year | $23.71 | N/A |
| Revenue Next Year | $9.22 | $7.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 92.93 | N/A |
| 52 Week Low | $3.70 | $5.00 |
| 52 Week High | $8.71 | $17.58 |
| Indicator | AIOT | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.72 | 37.17 |
| Support Level | $5.11 | $8.56 |
| Resistance Level | $5.44 | $10.08 |
| Average True Range (ATR) | 0.22 | 0.57 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 68.46 | 5.76 |
PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.